Tech Company M&A Transactions
Inviragen Acquisition
Inviragen was acquired by Takeda Pharmaceuticals. The acquisition was announced on 5/8/2013. The parties disclosed the acquisition price to be $250 million.
Transaction Overview
Company Name
Acquired By
Announced On
5/8/2013
Transaction Type
M&A
Amount
$250,000,000
M&A Terms
Takeda America Holdings, Inc., and Inviragen, Inc. have entered into a definitive agreement for Takeda to acquire Inviragen for an upfront payment of US$35 million, and future payments of up to US$215 million linked to the progress of clinical development and achievement of key commercial milestones.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
1613 Prospect Pkwy. 100
Fort Collins, CO 80525
USA
Fort Collins, CO 80525
USA
Phone
Website
Email Address
Overview
Inviragen, Inc. is committed to developing safe, effective vaccines to address this need. Inviragen is focused on developing life-saving vaccines to protect against emerging infectious diseases worldwide.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Dan Stinchcomb
Chief Medical Officer
Gilad Gordon
Chief Operating Officer
Joseph Santangelo
Chief Scientific Officer
Jorge Osorio
Browse more venture capital transactions:
Prev: 5/8/2013: Unifyo venture capital transaction
Next: 5/8/2013: YouEye venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs